Corporate & Commercial

The work of the Corporate and Commercial & Technology groups is often international in nature. We have extensive experience of cross-border transactions, including international M&A, establishing off-shore holding and investment structures, international tax planning, overseas joint ventures, and international supply and distribution agreements.We have numerous long-standing relationships with overseas clients, particularly foreign banks and trust companies and multi-national industrial and technology companies.

Like other teams in Hill Hofstetter we often co-ordinate and manage overseas law firms in delivering multi-country projects for our clients.

Examples of our recent international transactional and commercial work include:

• Advising a leading steel company on the purchase of a multi-national steel trading business.
• Representing numerous UK and overseas listed companies on cross-border M&A transactions involving the USA, Europe and Asia.
• Advising a Cayman company on the disposal of its UK logistics company to a French purchaser.
• Establishing a wide range of complex off-shore structures including trust companies, FURBS and partnerships, in a range of jurisdictions including Switzerland, the Caymans and BVI, the Channel Islands and the Isle of Man.
• The sale by an off shore trust company client of interests in a Dubai trading company to an investment bank.
• Leading the reorganisation of a Swiss/Cayman/BVI structure.
• Advising a US logistics company on the purchase of two distressed UK businesses.
• Representing a Swiss bank on a £200m inter-trust dispute.
• Advising various clients on international supply and distribution contracts.
• Representing a multi-national listed client on setting up manufacturing joint ventures in Sri Lanka.
• Running a multi-jurisdictional project for a US IT company on the data protection implications of launching archiving software across 16 European countries, managing all the in-country legal advisers.
• Advising a global pharmaceutical company on the impacts of EU privacy laws on medical research and the control and processing of medical data.